Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.
about
Interventions for actinic keratosesUnderstanding the molecular mechanisms of cancer prevention by dietary phytochemicals: From experimental models to clinical trialsMolecular cancer prevention: Current status and future directionsActinic keratosis: rationale and managementPharmacotherapy of actinic keratosis: an update.Safety, efficacy, and patient acceptability of imiquimod for topical treatment of actinic keratosesA network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in EuropeCost-utility of first-line actinic keratosis treatments in FinlandMethods and Results Report - Evidence and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis -International League of Dermatological Societies in cooperation with the European Dermatology Forum.New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel.A seamless phase I/II dose-finding trial assessing ingenol disoxate (LEO 43204) for field treatment of actinic keratosis on the scalp.Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.In-office Painless Aminolevulinic Acid Photodynamic Therapy: A Proof of Concept Study and Clinical Experience in More Than 100 PatientsEfficacy and Safety of 5-Fluorouracil 0.5%/Salicylic Acid 10% in the Field-Directed Treatment of Actinic Keratosis: A Phase III, Randomized, Double-Blind, Vehicle-Controlled Trial.Emerging drugs for actinic keratosis.Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.Current and emerging treatment strategies for the treatment of actinic keratosis.Resiquimod, a topical drug for viral skin lesions and skin cancer.Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring.Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.Ultraviolet radiation-induced non-melanoma skin cancer: Regulation of DNA damage repair and inflammationInhibition of keratinocyte proliferation by phospholipid-conjugates of a TLR7 ligand in a Myc-induced hyperplastic actinic keratosis model in the absence of systemic side effects.Imiquimod in dermatology: an overview.Comparison of the Treatment Guidelines for Actinic Keratosis: A Critical Appraisal and Review.Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% creamBritish Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017.[The aged scalp : A dermato-oncological focus point].Improving topical non-melanoma skin cancer treatment: In vitro efficacy of a novel guanosine-analog phosphonate.Imiquimod 2.5% and 3.75% Cream for the Treatment of Photodamage: A Meta-analysis of Efficacy and Tolerability in 969 Randomized Patients
P2860
Q24202407-340E3F04-0143-4451-9701-2312F07A5C44Q26765196-AA09D5B4-0213-42CE-BBC4-DF0490A370F6Q26797207-6378EDE0-19CD-4206-B0D1-BCDAE1258A36Q33785049-C9B45A7E-8075-493B-B9AD-DDC04B3ABF43Q34378153-DB5E6982-D3AC-42A4-B38B-3B0BD2FE6DF7Q35044103-384D8FE3-5DBD-4B19-A6D1-010A7686A04AQ35180653-14BA7179-08B7-4566-B318-EB097DD9F2FCQ35666250-CDE8E62E-2DE8-4F48-9C44-92B805575807Q35767304-528DF9D4-EA28-47EC-B18F-01D1AF7E3597Q36196699-0B77C0F7-29D7-4F19-919D-DE7C67171490Q36247044-1D27DDFA-AF4B-42F4-9D48-C366E7F768FEQ36373370-95A712C6-1AB1-4A72-AA53-AABF9952F0D5Q36631465-AB03D616-F30C-4FDB-A27E-B0D8AD683B0BQ37679944-41B57802-DEFD-4FAA-B711-706FBAA1DC48Q37776509-F7C3B49B-EE7E-47B0-AAC7-F12386548E74Q37831354-5C8A8E8F-D68D-4078-8D5D-165542E18BBDQ37857684-CBCC1F38-46DA-4032-8737-6458FF80A51BQ38064483-4458C290-95E6-4687-9337-E12CBC471B33Q38101606-AB1FD2BC-6D0A-4ADD-AB6F-4FBF7E553403Q38106805-A59550D3-9A33-4FA5-BE03-E905F498A4AFQ38340621-CAABCD37-1F83-4CBF-8DAC-4F7767AFA8AEQ38363654-70DABE9F-F860-41E7-B4C7-F4B2D8FDEC38Q38888889-18448598-6A9C-4F93-B002-8B903B14A49BQ39311286-701CA06A-DF70-4F6C-8C14-FAD7C12973DFQ40303153-F12A2C61-B63F-4F5C-8CC7-C61D7CACC8AEQ42488887-AC0DB0E6-EC60-4032-BDBE-E9766D36F024Q48063272-368473B8-6B75-41C3-BE02-988AC33F485AQ51821884-0DA34D16-FAD6-4F6D-9F3B-507B6BBAF596Q53625109-FB2BF902-2028-4328-A2BD-DFAF3381938BQ57494606-E9D6231E-D066-4A29-A2E5-602EF4937E4C
P2860
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 3-week cycles.
@ast
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 3-week cycles.
@en
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 3-week cycles.
@nl
type
label
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 3-week cycles.
@ast
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 3-week cycles.
@en
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 3-week cycles.
@nl
prefLabel
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 3-week cycles.
@ast
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 3-week cycles.
@en
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 3-week cycles.
@nl
P2093
P1476
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 3-week cycles.
@en
P2093
C William Hanke
Eggert Stockfleth
Kenneth R Beer
Sharon Levy
Theodore Rosen
P304
P356
10.1016/J.JAAD.2009.06.020
P407
P577
2010-02-04T00:00:00Z